Pityriasis rosea, COVID‐19 and vaccination: new keys to understand an old acquaintance
Open Access
- 26 April 2021
- journal article
- letter
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 35 (8) , E489-E491
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Human herpesvirus‐6, ‐7, and Epstein‐Barr virus reactivation in pityriasis rosea during COVID‐19Journal of Medical Virology, 2020
- Herpes simplex virus and cytomegalovirus reactivations among severe COVID-19 patientsCritical Care, 2020
- Pityriasis rosea as a cutaneous manifestation of COVID‐19 infectionJournal of the European Academy of Dermatology and Venereology, 2020
- Effectiveness of acyclovir in the treatment of pityriasis rosea. A systematic review and meta-analysisAnais Brasileiros de Dermatologia, 2018
- Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS): An Interplay among Drugs, Viruses, and Immune SystemInternational Journal of Molecular Sciences, 2017
- The Role of Cytokines, Chemokines, and Growth Factors in the Pathogenesis of Pityriasis RoseaMediators of Inflammation, 2015
- Vaccine‐induced pityriasis rosea and pityriasis rosea‐like eruptions: a review of the literatureJournal of the European Academy of Dermatology and Venereology, 2014
- Pityriasis rosea following human papillomavirus vaccinationThe Brazilian Journal of Infectious Diseases, 2014
- An Atypical Case of Pityriasis Rosea Gigantea after Influenza VaccinationCase Reports in Dermatology, 2014
- Pityriasis Rosea is Associated with Systemic Active Infection with Both Human Herpesvirus-7 and Human Herpesvirus-6Journal of Investigative Dermatology, 2002